Research - Oleander Technologies

Oleander Technologies Research

Redefining precision with a rapid, non-invasive method

A breakthrough in non-invasive cancer treatment that uses your body’s own biology to fight tumors — safely, selectively, and effectively.

Ongoing Research:

Human Pilot Study at CORE Medical Center (Tijuana, Mexico) An IRB-controlled pilot study conducted at CORE Medical Center, a state of the art hospital in Tijuana. This trial provides potentially life-saving TOL therapy to patients with a broad range of cancer types who would otherwise have limited access to treatment. The study also generates critical clinical data that informs how we continue to refine and optimize TOL for future large-scale clinical trials.
Human Clinical Trial (Australia) A TGA-compliant, IRB controlled, clinical trial evaluating the safety and efficacy of Targeted Osmotic Lysis in patients with squamous cell carcinoma. This trial represents a pivotal first step on the pathway to full regulatory approval of TOL therapy globally.
Animal Trials (Louisiana) Our Louisiana-based research site allows us to administer TOL therapy to companion animals diagnosed with various types of cancer. These trials serve as an important proving ground for our latest advances in TOL technology, enabling us to conduct early-stage safety and efficacy testing before advancing innovations into human trials.

TOL Developments:

TOL is a technology still in its early stages, and through our ongoing animal and human clinical trials, we continue to discover new ways to optimize treatment outcomes. At our Louisiana laboratory, we develop next-generation TOL treatment paradigms designed to enhance the overall therapeutic response across a variety of cancer types. This work focuses on further refining the pulsed electric field delivery system to improve penetration depth and precision targeting of specific subtypes of sodium channels within cancer cells.

Preclinical & Supporting Research:

A New Hope for Advanced Disease

Targeted Osmotic Lysis of Highly Invasive Breast Carcinomas Using Pulsed Magnetic Field Stimulation of Voltage-Gated Sodium Channels and Pharmacological Blockade of Sodium Pumps – See Article >

Selective lysis of breast carcinomas by simultaneous stimulation of sodium channels and blockade of sodium pumps – See Article >

Targeted Osmotic Lysis: A Novel Approach to Targeted Cancer Therapies – See Article >

The Role of Targeted Osmotic Lysis in the Treatment of Advanced Carcinoma in Companion Animals: A Case Series – See Article >

Cancer as a Channelopathy – Appreciation of Complimentary Pathways Provides a Different Perspective for Developing Treatments – See Article >

Effect of Cell Cycle on Cell Surface Expression of Voltage-Gated Sodium Channels and Na⁺, K⁺ -ATPase – See Article >

In vitro Characterization of a novel murine model of cancerous progression – See Article >

Safety evaluation of targeted osmotic lysis therapy in Beagles – See Article >

Use of Targeted Osmotic Lysis for the Treatment of Malignant Melanoma: Case Report – See Article >

Use of Targeted Osmotic Lysis for the Treatment of Cutaneous Squamous Cell Carcinoma – See Article >

Case Studies:

Emergency Use of Targeted Osmotic Lysis for the Treatment of a Patient with Aggressive Late-Stage Squamous Cell Carcinoma of the Cervix : See Article

Use of Targeted Osmotic Lysis for the Treatment of Malignant Melanoma: Case Report : See Article

Use of Targeted Osmotic Lysis for the Treatment of Cutaneous Squamous Cell Carcinoma : See Article

How TOL works

Advanced-stage cancer cells express 10 to 50 times more sodium channels in their cell membranes than do normal cells. By stimulating the opening of these channels and enabling the entry of large amounts of sodium while blocking the mechanism to expel the excess ions, Dr. Paul and Dr. Gould have been able to force cancer cells to burst, while leaving healthy cells unharmed. The treatment process uses a generic drug used to treat heart ailments (digoxin) and a new device that produces a pulsed electric field.